Leqvio

Oct 16, 2026

Summary siRNA and ASOs are emerging as major RNA-based therapeutic platforms, enabling targeted disease treatment by silencing or modulating gene expression. siRNA holds a commercial advantage in revenue generation and dosing convenience. Marketed siRNA drugs generated approximately $4.2 billion in disclosed...

Aug 07, 2026

Summary For nearly a decade, PCSK9 inhibitors have been highly effective at lowering LDL cholesterol, but their growth has been limited by the need for injections. The U.S. FDA approval of Merck’s LIPFENDRA (enlicitide) changes that by introducing the first oral PCSK9 inhibitor, marking a major shift from ne...